{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:06:33Z","timestamp":1786993593543,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014261","name":"National Institute for Health Care Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jval.2021.02.008","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T18:35:54Z","timestamp":1620671754000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a \u201cShared Savings\u201d Approach to Cost Offsets"],"prefix":"10.1016","volume":"24","author":[{"given":"Richard H.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun M.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D.","family":"Whittington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2021.02.008_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","article-title":"Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system","volume":"22","author":"Quinn","year":"2019","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2021.02.008_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1586\/14737167.2015.1039519","article-title":"How do we value a cure?","volume":"15","author":"Husereau","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2021.02.008_bib3","series-title":"The Value of Innovation. Report by the Decision Support Unit","author":"Claxton","year":"2009"},{"issue":"7","key":"10.1016\/j.jval.2021.02.008_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2021.02.008_bib5","series-title":"Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products","author":"Crabb","year":"2016"},{"key":"10.1016\/j.jval.2021.02.008_bib6","author":"Chapman"},{"issue":"7","key":"10.1016\/j.jval.2021.02.008_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10198-019-01032-7","article-title":"Is rate of return pricing a useful approach when value-based pricing is not appropriate?","volume":"20","author":"Drummond","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2021.02.008_bib8","author":"Ellis"},{"key":"10.1016\/j.jval.2021.02.008_bib9","author":"Rind"},{"key":"10.1016\/j.jval.2021.02.008_bib10","author":"Tice"},{"issue":"6","key":"10.1016\/j.jval.2021.02.008_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jval.2019.01.012","article-title":"New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?","volume":"22","author":"Pearson","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2021.02.008_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jval.2019.03.013","article-title":"Uncertainty and cures: discontinuation, irreversibility, and outcomes-based payments: what is different about a one-off treatment?","volume":"22","author":"Towse","year":"2019","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2021.02.008_bib14","first-page":"836","article-title":"Updated trends in US brand-name and generic drug competition","volume":"19","author":"Grabowski","year":"2016","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2021.02.008_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamainternmed.2014.7968","article-title":"Variations in time of market exclusivity among top-selling prescription drugs in the United States","volume":"175","author":"Wang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jval.2021.02.008_bib16","author":"Kesselheim"},{"issue":"1","key":"10.1016\/j.jval.2021.02.008_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd3277","article-title":"Data exclusivity for biologics","volume":"10","author":"Grabowski","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jval.2021.02.008_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/cer-2017-0068","article-title":"Gene therapy: evidence, value and affordability in the US health care system","volume":"7","author":"Hampson","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"issue":"5","key":"10.1016\/j.jval.2021.02.008_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: no easy answers","volume":"21","author":"Ollendorf","year":"2018","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521001583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521001583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:23:33Z","timestamp":1761096213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1098301521001583"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.02.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a \u201cShared Savings\u201d Approach to Cost Offsets","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.04.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}